Have a personal or library account? Click to login

Multiparametric MRI - local staging of prostate cancer and beyond

Open Access
|May 2019

References

  1. Mottet N, van den Bergh RCN, Briers E, Bourke L, Cornford P, De Santis M, et al. EAU - ESTRO - ESUR - SIOG guidelines on prostate cancer 2018. In: European Association of Urology guidelines 2018 Edition Arnhem, The Netherlands: European Association of Urology Guidelines Office; 2018.
  2. Brizmohun Appayya M, Adshead J, Ahmed HU, Allen C, Bainbridge A, Barrett T, et al. National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting. BJU Int 2018; 122: 13-25. 10.1111/bju.14361
  3. Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol 2007; 25: 110-4. 10.1016/j.urolonc.2006.06.003
  4. Godoy G, Tareen BU, Lepor H. Site of positive surgical margins influences biochemical recurrence after radical prostatectomy. BJU Int 2009; 104: 1610-4. 10.1111/j.1464-410X.2009.08688.x
  5. Epstein JI, Partin AW, Potter SR, Walsh PC. Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology 2000; 56: 283-8. 10.1016/S0090-4295(00)00640-3
  6. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003; 170: 1798-803. 10.1097/01.ju.0000091805.98960.13
  7. Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE, et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989; 142: (2 Part 1)332-6. 10.1016/S0022-5347(17)38748-7
  8. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869-75. 10.1016/j.juro.2010.10.057
  9. Morlacco A, Sharma V, Viers BR, Rangel LJ, Carlson RE, Froemming AT, et al. The incremental role of magnetic resonance imaging for prostate cancer staging before radical prostatectomy. Eur Urol 2017; 71: 701-4. 10.1016/j.eururo.2016.08.015
  10. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95: 751-6. 10.1111/j.1464-410X.2005.05394.x
  11. Augustin H, Fritz GA, Ehammer T, Auprich M, Pummer K. Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the partin tables. Acta Radiol 2009; 50: 562-9. 10.1080/02841850902889846
  12. Gupta RT, Faridi KF, Singh AA, Passoni NM, Garcia-Reyes K, Madden JF, et al. Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy. Urol Oncol Semin Orig Investig 2014; 32: 1292-9. 10.1016/j.urolonc.2014.04.017
  13. Rayn KN, Bloom JB, Gold SA, Hale GR, Baiocco JA, Mehralivand S, et al. Added value of multiparametric magnetic resonance imaging to clinical nomograms for predicting adverse pathology in prostate cancer. J Urol 2018; 200: 1041-7. 10.1016/j.juro.2018.05.094
  14. Boehmer D, Maingon P, Poortmans P, Baron M-H, Miralbell R, Remouchamps V, et al. Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol 2006; 79: 259-69. 10.1016/j.radonc.2006.05.012
  15. Mottet N, van der Poel HG, Rouvière O, Matveev VB, Schoots IG, Briers E, et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol 2017; 72: 84-109. 10.1016/j.eururo.2016.12.003
  16. Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, et al. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 245-53. 10.3322/caac.21391
  17. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al, editors. AJCC cancer staging manual. 8th edition. New York: Springer; 2017.
  18. Giganti F, Moore CM, Punwani S, Allen C, Emberton M, Kirkham A. The natural history of prostate cancer on MRI: lessons from an active surveillance cohort. Prostate Cancer Prostatic Dis 2018; 21: 556-63. 10.1038/s41391-018-0058-5
  19. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS prostate imaging - reporting and data system: 2015, Version 2. Eur Urol 2016; 69: 16-40. 10.1016/j.eururo.2015.08.052
  20. Rouvière O, Hartman RP, Lyonnet D. Prostate MR imaging at high-field strength: evolution or revolution? Eur Radiol 2006; 16: 276-84. doi:org/10.1007/s00330-005-2893-8
  21. Turkbey B, Merino MJ, Gallardo EC, Shah V, Aras O, Bernardo M, et al. Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging 2014; 39: 1443-8. 10.1002/jmri.24317
  22. Czarniecki M, Caglic I, Grist JT, Gill AB, Lorenc K, Slough RA, et al. Role of PROPELLER-DWI of the prostate in reducing distortion and artefact from total hip replacement metalwork. Eur J Radiol 2018; 102: 213-9. doi:org/10.1016/j.ejrad.2018.03.021
  23. Gill AB, Czarniecki M, Gallagher FA, Barrett T. A method for mapping and quantifying whole organ diffusion-weighted image distortion in MR imaging of the prostate. Sci Rep 2017; 7: 12727. 10.1038/s41598-017-13097-6
  24. Barrett T, Turkbey B, Choyke PL. PI-RADS version 2: what you need to know. Clin Radiol 2015; 70: 1165-76. 10.1016/j.crad.2015.06.093
  25. Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019; 0232: 1-12. 10.1016/j.eururo.2019.02.033
  26. Caglic I, Povalej Brzan P, Warren AY, Bratt O, Shah N, Barrett T. Defining the incremental value of 3D T2-weighted imaging in the assessment of prostate cancer extracapsular extension. Eur Radiol 2019. [Epub ahead of print]. 10.1007/s00330-019-06070-6
  27. Thoeny HC, Froehlich JM, Triantafyllou M, Huesler J, Bains LJ, Vermathen P, et al. Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging. Radiology 2014; 273: 125-35. 10.1148/radiol.14132921
  28. Slough RA, Caglic I, Hansen NL, Patterson AJ, Barrett T. Effect of hyoscine butylbromide on prostate multiparametric MRI anatomical and functional image quality. Clin Radiol 2018; 73: 216.e9-14. 10.1016/j.crad.2017.07.013
  29. Ullrich T, Quentin M, Schmaltz AK, Arsov C, Rubbert C, Blondin D, et al. Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate. Eur Radiol 2018; 28: 17-23. org/10.1007/s00330-017-4940-7
  30. Caglic I, Barrett T. Optimising prostate mpMRI: prepare for success. Clin Radiol 2019. [Epub ahead of print]. 10.1016/j.crad.2018.12.003
  31. Dyde R, Chapman AH, Gale R, Mackintosh A, Tolan DJM. Precautions to be taken by radiologists and radiographers when prescribing hyoscine-N-butyl-bromide. Clin Radiol 2008; 63: 739-43. org/10.1016/j.crad.2008.02.008
  32. Ayala AG, Ro JY, Babaian R, Troncoso P, Grignon DJ. The prostatic capsule. Am J Surg Pathol 1989; 13: 21-7. 10.1097/00000478-19890100000003
  33. McNeal JE. Normal histology of the prostate. Am J Surg Pathol 1988; 12: 619-33. 10.1097/00000478-198808000-00003
  34. Ball MW, Partin AW, Epstein JI. Extent of extraprostatic extension independently influences biochemical recurrence-free survival: evidence for further PT3 subclassification. Urology 2015; 85: 161-4. org/10.1016/j.urology.2014.08.025
  35. Rosenkrantz AB, Shanbhogue AK, Wang A, Kong MX, Babb JS, Taneja SS. Length of capsular contact for diagnosing extraprostatic extension on prostate MRI: assessment at an optimal threshold. J Magn Reson Imaging 2016; 43: 990-7. 10.1002/jmri.25040
  36. Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int 2013; 111: 22-9. 10.1111/j.1464-410X.2012.11324.x
  37. Turkbey B, Mani H, Aras O, Ho J, Hoang A, Rastinehad AR, et al. Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology 2013; 268: 144-52. 10.1148/radiol.13121325
  38. de Rooij M, Hamoen EHJ, Witjes JA, Barentsz JO, Rovers MM. Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol 2016; 70: 233-45. 10.1016/j.eururo.2015.07.029
  39. Lawrence EM, Gallagher FA, Barrett T, Warren AY, Priest AN, Goldman DA, et al. Preoperative 3-T diffusion-weighted MRI for the qualitative and quantitative assessment of extracapsular extension in patients with intermediate - or high-risk prostate cancer. AJR Am J Roentgenol 2014; 203: W280-6. 10.2214/AJR.13.11754
  40. Boesen L, Chabanova E, Løgager V, Balslev I, Mikines K, Thomsen HS. Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: a correlation with histopathology. Eur Radiol 2015; 25: 1776-85. 10.1007/s00330-014-3543-9
  41. Schieda N, Quon JS, Lim C, El-Khodary M, Shabana W, Singh V, et al. Evaluation of the European Society of Urogenital Radiology (ESUR) PI-RADS scoring system for assessment of extra-prostatic extension in prostatic carcinoma. Eur J Radiol 2015; 84: 1843-8. 10.1016/j.ejrad.2015.06.016
  42. Baco E, Rud E, Vlatkovic L, Svindland A, Eggesbø HB, Hung AJ, et al. Predictive value of magnetic resonance imaging determined tumor contact length for extracapsular extension of prostate cancer. J Urol 2015; 193: 46672. 10.1016/j.juro.2014.08.084
  43. Woo S, Kim SY, Cho JY, Kim SH. Length of capsular contact on prostate MRI as a predictor of extracapsular extension: which is the most optimal sequence? Acta Radiol 2017; 58: 489-97. 10.1177/0284185116658684
  44. Matsuoka Y, Ishioka J, Tanaka H, Kimura T, Yoshida S, Saito K, et al. Impact of the Prostate Imaging Reporting and Data System, Version 2, on MRI diagnosis for extracapsular extension of prostate cancer. AJR Am J Roentgenol 2017; 209: W76-84. org/10.2214/AJR.16.17163
  45. Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergenvan de Kaa CA, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011; 259: 453-61. 10.1148/radiol.11091409
  46. Verma S, Rajesh A, Morales H, Lemen L, Bills G, Delworth M, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol 2011; 196: 374-81. 10.2214/AJR.10.4441
  47. Kim CK, Park SY, Park JJ, Park BK. Diffusion-weighted MRI as a predictor of extracapsular extension in prostate cancer. AJR Am J Roentgenol 2014; 202: W270-6. 10.2214/AJR.13.11333
  48. Woo S, Cho JY, Kim SY, Kim SH. Extracapsular extension in prostate cancer: added value of diffusion-weighted MRI in patients with equivocal findings on T2-weighted imaging. AJR Am J Roentgenol 2015; 204: W168-75. 10.2214/AJR.14.12939
  49. Giganti F, Coppola A, Ambrosi A, Ravelli S, Esposito A, Freschi M, et al. Apparent diffusion coefficient in the evaluation of side-specific extracapsular extension in prostate cancer: development and external validation of a nomogram of clinical use. Urol Oncol Semin Orig Investig 2016; 34: 291. e9-17. 10.1016/j.urolonc.2016.02.015
  50. Barrett T, Priest AN, Lawrence EM, Goldman DA, Warren AY, Gnanapragasam VJ, et al. Ratio of tumor to normal prostate tissue apparent diffusion coefficient as a method for quantifying DWI of the prostate. AJR Am J Roentgenol 2015; 205: W585-93. 10.2214/AJR.15.14338
  51. Rosenkrantz AB, Neil J, Kong X, Melamed J, Babb JS, Taneja SS, et al. Prostate cancer: comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection. AJR Am J Roentgenol 2010; 194: 446-52. 10.2214/AJR.09.3217
  52. Itatani R, Namimoto T, Takaoka H, Katahira K, Morishita S, Kitani K, et al. Extracapsular extension of prostate cancer: diagnostic value of combined multiparametric magnetic resonance imaging and isovoxel 3-dimensional T2-weighted imaging at 1.5 T. J Comput Assist Tomogr 2015; 39: 37-43. 10.1097/RCT.0000000000000172
  53. Liberatore M, Delongchamps NB, Eiss D, Beuvon F, Zerbib M, Flam T, et al. Endorectal 3D T2-weighted 1mm-slice thickness MRI for prostate cancer staging at 1.5Tesla: should we reconsider the indirects signs of extracapsular extension according to the D’Amico tumor risk criteria? Eur J Radiol 2011; 81: e591-7. 10.1016/j.ejrad.2011.06.056
  54. Jäderling F, Nyberg T, Öberg M, Carlsson S, Skorpil M, Blomqvist L. Accuracy in local staging of prostate cancer by adding a three-dimensional T2-weighted sequence with radial reconstructions in magnetic resonance imaging. Acta Radiol Open 2018; 7: 205846011875460. 10.1177/2058460118754607
  55. Peng Y, Schmid-Tannwald C, Wang S, Antic T, Jiang Y, Eggener S, et al. Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. Radiology 2013; 267: 797-806. 10.1148/radiol.13121319
  56. Chan KK, Choi D, Byung KP, Ghee YK, Hyo KL. Diffusion-weighted MR imaging for the evaluation of seminal vesicle invasion in prostate cancer: initial results. J Magn Reson Imaging 2008; 28: 963-9. 10.1002/jmri.21531
  57. Potter SR, Epstein JI, Partin AW. Seminal vesicle invasion by prostate cancer: prognostic significance and therapeutic implications. Rev Urol 2000; 2: 190-5. PMID: 16985773
  58. Wang L, Hricak H, Kattan MW, Chen HN, Kuroiwa K, Eisenberg HF, et al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology 2007; 242: 182-8. 10.1148/radiol.2421051254
  59. Grivas N, Hinnen K, de Jong J, Heemsbergen W, Moonen L, Witteveen T, et al. Seminal vesicle invasion on multi-parametric magnetic resonance imaging: correlation with histopathology. Eur J Radiol 2018; 98: 107-12. 10.1016/j.ejrad.2017.11.013
  60. Roethke M, Kaufmann S, Kniess M, Ketelsen D, Claussen CD, Schlemmer HP, et al. Seminal vesicle invasion: accuracy and analysis of infiltration patterns with high-spatial resolution T2-weighted sequences on endorectal magnetic resonance imaging. Urol Int 2014; 92: 294-9. 10.1159/000353968
  61. Ohori M, Scardino PT, Lapin SL, Seale-Hawkins C, Link J, Wheeler TM. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol 1993; 17: 1252-61. 10.1097/00000478-199312000-00006
  62. Jung DC, Lee HJ, Kim SH, Choe GY, Lee SE. Preoperative MR imaging in the evaluation of seminal vesicle invasion in prostate cancer: pattern analysis of seminal vesicle lesions. J Magn Reson Imaging 2008; 28: 144-50. 10.1002/jmri.21422
  63. Soylu FN, Peng Y, Jiang Y, Wang S, Schmid-Tannwald C, Sethi I, et al. Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. Radiology 2013; 267: 797-806. 10.1148/radiol.13121319
  64. Gofrit ON, Zorn KC, Taxy JB, Zagaja GP, Steinberg GD, Shalhav AL. The dimensions and symmetry of the seminal vesicles. J Robot Surg 2009; 3: 29-33. 10.1007/s11701-009-0134-x
  65. Saliken JC, Gray RR, Donnelly BJ, Owen R, White LJ, Ali-Ridha N, et al. Extraprostatic biopsy improves the staging of localized prostate cancer. Can Assoc Radiol J 2000; 51: 114-20. PMID: 10786920
  66. Barrett T, Tanner J, Gill AB, Slough RA, Wason J, Gallagher FA. The longitudinal effect of ejaculation on seminal vesicle fluid volume and whole-prostate ADC as measured on prostate MRI. Eur Radiol 2017; 27: 5236-43. 10.1007/s00330-017-4905-x
  67. Medved M, Sammet S, Yousuf A, Oto A. MR Imaging of the prostate and adjacent anatomic structures before, during, and after ejaculation: qualitative and quantitative evaluation. Radiology 2014; 271: 452-60. 10.1148/radiol.14131374
  68. Shin T, Kaji Y, Shukuya T, Nozaki M, Soh S, Okada H. Significant changes of T2 value in the peripheral zone and seminal vesicles after ejaculation. Eur Radiol 2018; 28: 1009-15. 10.1007/s00330-017-5077-4
  69. Kabakus IM, Borofsky S, Mertan FV, Greer M, Daar D, Wood BJ, et al. Does abstinence from ejaculation before prostate MRI improve evaluation of the seminal vesicles? AJR Am J Roentgenol 2016; 207: 1205-9. 10.2214/AJR.16.16278
  70. McMahon CJ, Rofsky NM, Pedrosa I. Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging. Radiology 2010; 254: 31-46. 10.1148/radiol.2541090361
  71. Joniau S, Van den Bergh L, Lerut E, Deroose CM, Haustermans K, Oyen R, et al. Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 2013; 63: 450-8. 10.1016/j.eururo.2012.06.057
  72. Briganti A, Suardi N, Capogrosso P, Passoni N, Freschi M, Di Trapani E, et al. Lymphatic spread of nodal metastases in high-risk prostate cancer: the ascending pathway from the pelvis to the retroperitoneum. Prostate 2012; 72: 186-92. 10.1002/pros.21420
  73. Barentsz JO, Severens JL, Hoogeveen YL, Hövels AM, Adang EM, Jager GJ, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63: 387-95. 10.1016/j.crad.2007.05.022
  74. Vag T, Heck MM, Beer AJ, Souvatzoglou M, Weirich G, Holzapfel K, et al. Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT. Eur Radiol 2014; 24: 1821-6. 10.1007/s00330-014-3240-8
  75. Eiber M, Beer AJ, Holzapfel K, Tauber R, Ganter C, Weirich G, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol 2010; 45: 15-23. 10.1097/RLI.0b013e3181bbdc2f
  76. Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, Weirich G, et al. Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in 11C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol 2011; 13: 352-61. 10.1007/s11307-010-0337-6
  77. Vallini V, Ortori S, Boraschi P, Manassero F, Gabelloni M, Faggioni L, et al. Staging of pelvic lymph nodes in patients with prostate cancer: usefulness of multiple b value SE-EPI diffusion-weighted imaging on a 3.0 T MR system. Eur J Radiol Open 2016; 3: 16-21. 10.1016/j.ejro.2015.11.004
  78. Roy C, Bierry G, Matau A, Bazille G, Pasquali R. Value of diffusion-weighted imaging to detect small malignant pelvic lymph nodes at 3 T. Eur Radiol 2010; 20: 1803-11. 10.1007/s00330-010-1736-4
  79. Caglic I, Barrett T. Diffusion-weighted imaging (DWI) in lymph node staging for prostate cancer. Transl Androl Urol 2018; 7: 814-23. 10.21037/tau.2018.08.04
  80. Abdel Razek AAK, Soliman NY, Elkhamary S, Alsharaway MK, Tawfik A. Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 2006; 16: 1468-77. 10.1007/s00330-005-0133-x
  81. Muenzel D, Duetsch S, Fauser C, Slotta-Huspenina J, Gaa J, Rummeny EJ, et al. Diffusion-weighted magnetic resonance imaging in cervical lymphadenopathy: report of three cases of patients with bartonella henselae infection mimicking malignant disease. Acta Radiol 2009; 50: 914-6. 10.1080/02841850903061445
  82. Kwee TC, Takahara T, Luijten PR, Nievelstein RAJ. ADC measurements of lymph nodes: inter- and intra-observer reproducibility study and an overview of the literature. Eur J Radiol 2010; 75: 215-20. 10.1016/j.ejrad.2009.03.026
  83. Braithwaite AC, Dale BM, Boll DT, Merkle EM. Short- and midterm reproducibility of apparent diffusion coefficient measurements at 3.0-T diffusion-weighted imaging of the abdomen. Radiology 2009; 250: 459-65. 10.1148/radiol.2502080849
  84. Rosenkrantz AB, Oei M, Babb JS, Niver BE, Taouli B. Diffusion-weighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. J Magn Reson Imaging 2011; 33: 128-35. 10.1002/jmri.22395
  85. Sadinski M, Medved M, Karademir I, Wang S, Peng Y, Jiang Y, et al. Short-term reproducibility of apparent diffusion coefficient estimated from diffusion-weighted MRI of the prostate. Abdom Imaging 2015; 40: 2523-8. 10.1007/s00261-015-0396-x
  86. von Below C, Daouacher G, Wassberg C, Grzegorek R, Gestblom C, Sörensen J, et al. Validation of 3 T MRI including diffusion-weighted imaging for nodal staging of newly diagnosed intermediate- and high-risk prostate cancer. Clin Radiol 2016; 71: 328-34. 10.1016/j.crad.2015.12.001
  87. Sushentsev N, Martin H, Rimmer Y, Barrett T. Added value of diffusion-weighted MRI for nodal radiotherapy planning in pelvic malignancies. Clin Transl Oncol 2019. [Epub ahead of print]. doi.org/10.1007/s12094-019-02068-0
  88. Zacharias C, Kunder C, Giesel F, Daniel B, Hatami N, Harrison C, et al. Gallium 68 PSMA-11 PET/MR imaging in patients with intermediate- or high-risk prostate cancer. Radiology 2018; 288: 495-505. org/10.1148/radiol.2018172232
  89. Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, et al. Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 70-83. 10.1007/s00259-015-3206-3
  90. Baltzer P, Kenner L, Hartenbach M, Mitterhauser M, Goldner GM, Grahovac M, et al. PSMA Ligand PET/MRI for primary prostate cancer: staging performance and clinical impact. Clin Cancer Res 2018; 24: 6300-7. 10.1158/1078-0432.ccr-18-0768
  91. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-9. 10.1056/NEJMoa022749
  92. Birkhäuser FD, Studer UE, Froehlich JM, Triantafyllou M, Bains LJ, Petralia G, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 2013; 64: 953-60. 10.1016/j.eururo.2013.07.032
  93. Thoeny HC, Triantafyllou M, Birkhaeuser FD, Froehlich JM, Tshering DW, Binser T, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009; 55: 761-9. 10.1016/j.eururo.2008.12.034
  94. Fortuin AS, Brüggemann R, van der Linden J, Panfilov I, Israël B, Scheenen TWJ, et al. Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block. Wiley Interdiscip Rev Nanomedicine Nanobiotechnology 2018; 10: e1471. 10.1002/wnan.1471
  95. National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management, clinical guideline [CG175], 2014. [cited 2019 March 28]. Available at: http://www.nice.org.uk/guidance/cg175/chapter/1-recommendations
  96. Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol 2014; 43: 1503-13. 10.1007/s00256-014-1903-9
  97. Padhani AR, Koh D-M, Collins DJ. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 2011; 261: 700-18. 10.1148/radiol.11110474
  98. Padhani AR, Lecouvet FE, Tunariu N, Koh D-M, De Keyzer F, Collins DJ, et al. METastasis Reporting and Data System for Prostate Cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 2017; 71: 81-92. 10.1016/j.eururo.2016.05.033
  99. Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F, et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 2012; 62: 68-75. 10.1016/j.eururo.2012.02.020
  100. Pasoglou V, Michoux N, Peeters F, Larbi A, Tombal B, Selleslagh T, et al. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. Radiology 2015; 275: 155-66. 10.1148/radiol.14141242
  101. Larbi A, Pasoglou V, Triqueneaux P, Cyteval C, Tombal B, Omoumi P, et al. Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences. Eur Radiol 2018. [Epub ahead of print]. 10.1007/s00330-018-5796-1
DOI: https://doi.org/10.2478/raon-2019-0021 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 159 - 170
Submitted on: Mar 29, 2019
Accepted on: Apr 15, 2019
Published on: May 8, 2019
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2019 Iztok Caglic, Viljem Kovac, Tristan Barrett, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.